Keywords
substance
intravenous
opiate
Abstract
Objective: People who inject drugs have major contribution to a rise in hepatitis C virus (HCV) infections. Despite efficacy and safety of direct-acting antiviral (DAA) therapies, patients may have difficulties to receive treatment. In this study we aimed to examine the effect of clinical variables in substance users to access to antiviral treatment and the treatment rate.
Method: In this retrospective study, we examined the files of 5586 patients who admitted to Outpatient Treatment Center (OTC) between July 2020-April 2021 and files of 121 patients with positive Anti-HCV results were included. All patients had been routinely assessed by Addiction Profile Index (API) and Adult Attention Deficit Hyperactivity Disorder Self-Rating Scale (ASRS)..
Results: Of 121 patients, the most used substance was opiate. Because of the insurance restrictions, DAA treatment might be prescribed in only tertiary referral hospitals. All patients had been referred to a tertiary referral hospital. The mean duration from Anti-HCV testing to treatment was 190.3 days. Actively iv substance users were more likely to use substances every day ( 81.5 % vs 41.5%), start using the current substance at younger age (19.1 vs 20.9), have higher total API scores, have higher depression (4.7 vs 3.7), anxiety subscale scores, and ASRS-A scores (11.3 vs 8.3). Actively iv substance users were no more likely to have longer Anti-HCV – treatment duration (100.4 ve 254.5) and have worse treatment completion rates (% 100 vs 67.7).
Conclusion: According to research findings, young adults' expectations to obtain social status and social conformity through the acquisition of a product may affect spending time for online shopping and they may lose control of the use of credit cards..
References
Scott N, Doyle JS, Wilson DP, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy 2017; 47: 107-116.
Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9(7): e103345.
Iversen J, Grebely J, Catlett B, et al. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Int J Drug Policy 2017; 47: 77-85.
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017; 166(9): 637-648.
Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn 2017; 17: 1109-1115.
World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis. Geneva: WHO, 2016.
Lopes H, Baptista-Leite R, Franco D, et al. Let’s End HepC: Modelling public health epidemiological policies applied to hepatitis C in Spain. Front Public Health 2022; 9: 735572.
World Health Organization. Global Hepatitis Report, 2017. Geneva: WHO, 2017.
Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204(1): 74-83.
Mittal A, Kosinski KC, Stopka TJ. HCV treatment access among Latins who inject drugs: qualitative findings from Boston, Massachusetts. Harm Reduct J 2019; 16: 1–9.
Versfeld A, McBride A, Scheibe A, Spearman CW. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Harm Reduct J 2020; 17(1): 39.
Butsashvili M, Abzianidze T, Kamkamidze G, et al. Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia. Subst Abuse Treat Prev Policy 2022; 17(1): 23.
Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2015; 35(2): 245-256.
Doğan S, Öncü B, Varol-Saraçoğlu G, Küçükgöncü S. Validity and reliability of the Turkish version of the Adult ADHD Self-Report Scale. Anadolu Psikiyatri Derg 2009; 10: 78-87.
Ögel K, Evren C, Karadağ F, Tamar Gürol D. Development, Validity and Reliability Study of Addiction Profile Index. Turk Psikiyatri Derg 2012; 23(4): 263-275.
Butler K, Day C, Dietze P, et al. The potential reach of opioid substitution settings to deliver HCV care to people who inject drugs in Australia. J Subst Abuse Treat 2015; 58: 90-94.
Akiyama MJ, Lipsey D, Heo M, et al. Low Hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy. Clin Inf Dis 2020; 70(12): 2695-2702.
Robaeys G, Bielen R, Azar DG, et al. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol 2016; 65(6): 1094-1103.
Sanvisens A, Rivas I, Faure E, et al. Monitoring hepatitis C virus treatment rates in an opioid treatment program: A longitudinal study. World J Gastroenterol 2020; 26(38): 5874-5883.
Erman Daloğlu A, Parkan ÖM, Erdoğan A, et al. Distribution of hepatitis C virus genotypes among intravenous drug and non-drug user patients. Mikrobiyol Bult 2021; 55(1): 30-40.
Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2015; 57 (Suppl 2): 80-89.
Trooskin SB, Dore G, Kostman J. We must do better: Addressing HCV treatment barriers in persons who inject drugs in the United States. J Infect Dis 2020; 222(S9): 773-781.
Rosenthal ES, Silk R, Mathur P, et al. Concurrent initiation of hepatitis c and opioid use disorder treatment in people who inject drugs. Clin Infect Dis 2020; 71(7): 1715–1722.
Akiyama MJ, Norton BL, Arnsten JH, et al. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. Ann Intern Med 2019; 170: 594-603.
Muller A, Vlahov D, Akiyama MJ, Kurth A. Hepatitis C reinfection in people who inject drugs in resource-limited countries: a systematic review and analysis. Int J Environ Res Public Health 2020; 17(14): 49-51.
Zeremski M, Zibbell JE, Martinez AD, et al. Hepatitis C Virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol 2013; 19: 7846-7851.
Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004; 65 (Suppl 3): 38-45.
Tapert SF, Baratta MV, Abrantes AM, Brown SA. Attention dysfunction predicts substance involvement in community youths. J Am Acad Child Adolesc Psychiatry 2020; 41(6): 680-686.
Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2022; 45(4): 265-273.
Pericot-Valverde I, Heo M, Niu J, et al. Relationship between depressive symptoms and adherence to direct-acting antivirals: Implications for Hepatitis C treatment among people who inject drugs on medications for opioid use disorder. Drug Alcohol Depend 2022; 14: 234.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Dependence